" Cardiovascular disease, especially coronary heart disease (CHD) is a very important health problem in Singapore today. Coronary heart disease is second only to cancer as a leading cause of mortality in this country...Lipid disorders (dyslipidaemia) play a major role in the pathogenesis of CHD. [...]

This review of the MOH Clinical Practice Guidelines on Lipids, first published in 2001, ... incorporates the best available evidence from the scientific literature, appraised by the comprehensive expertise of the expert workgroup that revised the guidelines. They have interpreted the evidence in our local context and drafted practical recommendations on managing patients with lipid abnormalities.

These guidelines address important issues in diagnosis and managing patients with dyslipidaemia according to the individual’s co-existing risk factors for CHD. A key change is the addition of recently developed risk score tables [developed by the Singapore Cardiovascular Disease Risk Score workgroup] to estimate 10-year CHD risk in individuals with two or more risk factors. Cost-effectiveness is an important factor that has been considered by the workgroup in making recommendations. [...]"